InvestorsHub Logo
icon url

wimuskyfisherman

06/10/19 1:08 PM

#38591 RE: numbersarefun #38590

Numbers- Odidi and company have certainly failed on monetizing their ANDA pipeline. They should just sell it off. I am guessing these items have been removed from the website as they are trying to reinvent themselves as a cannabis company and removed the evidence of past failure. Odidi and company have no market vision. They just copy what is already being done. And their copy attempts are not executed fast enough to actually profit. Heaven knows what they are working on in the cannabis realm. But it is already a crowded space. And as far as I know, most cannabis benefits are anecdotal at best. The only FDA approved drug in this space is for seizures. For once I would like to see Odidi at the front of something innovative. But so far, just me too stuff. The three I's... First come the Innovators, then the Imitators and then the Idiots... I would have to say Odidi falls between Imitator and Idiot.
icon url

doogdilinger

06/10/19 1:54 PM

#38593 RE: numbersarefun #38590

Hard to believe this bio company reached such a point of total and complete absurdity that they're resorting to hiding their ugly list of failures from the public domain, while simultaneously pumping out CBD/MJ sector fluff that will never amount to anything like their badly failed and exposed ANDA and NDA pipelines.

10 and a half years since IPCI went public, and the only thing Odidiot ever partially succeeded at was the 180 days of exclusivity on 2 strengths of FocalinXR way way back at the end of November 2013.

Beyond that mini-success over 5 and a half years ago, every single other thing Odidiot blew $10's of millions of dollars in dilutive funding on was a total and complete across the board failure.

icon url

numbersarefun

07/13/19 4:44 PM

#38611 RE: numbersarefun #38590

IPCI's Ranexa NOT among 2 additional Approvals 7/5/2019. GlenmarkPharms got approval on July 5, 2019, last week. SciegenPharms got approval in June 2019. So now there are a total of 7 ANDAs for Ranexa. I hope IPCI gets approval soon, and not years late.

PDUFA is 47 days away on May 28, 2019. I still have not heard of any FDA AdCom (Advisory Committee) meeting scheduled yet.

Intellipharmaceutics announced 2nd Quarter 2019 results:
https://www.intellipharmaceutics.com/news-media/press-releases/detail/206/intellipharmaceutics-announces-second-quarter-2019-results